Leaflet VESOMNI 6mg / 0.4mg prolonged-release tablets
Indicated for: benign prostatic hyperplasia
Route of administration: oral
Substance: solifenacin succinate + tamsulosin (urinary antimuscarinic + alpha-1 blocker)
ATC: G04CA53 (Genito urinary system and sex hormones | Drugs used in benign prostatic hypertrophy | Alpha-adrenoreceptor antagonists)
Use caution if you have glaucoma or increased eye pressure.
May cause dry mouth, constipation, urinary retention, or blurred vision.
Older people may have an increased risk of side effects.
The combination of solifenacin succinate + tamsulosin is indicated for the treatment of moderate to severe bladder storage symptoms (urinary urgency, increased urinary frequency) and bladder emptying symptoms associated with benign prostatic hyperplasia (BPH) in men who are inadequately responsive to monotherapy.
These drugs have complementary and independent mechanisms of action in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with bladder storage symptoms.
Solifenacin is a competitive and selective muscarinic receptor antagonist and does not show any relevant affinity for other receptors, enzymes or ion channels that have been tested. Solifenacin shows the highest affinity for muscarinic M3 receptors, followed by muscarinic M1 and M2 receptors.
Tamsulosin is an alpha1-adrenergic receptor (AR) antagonist. It binds selectively and competitively to post-synaptic alpha1-adrenergic receptors, especially the alpha-1A and alpha-1D subtypes, and is a potent antagonist in the lower urinary tract.
General data about VESOMNI 6mg / 0.4mg
- Substance: solifenacin succinate + tamsulosin
- Date of latest medicines list: 01-06-2026
- Product code: W61041005
- Concentration: 6mg / 0.4mg
- Pharmaceutical form: prolonged-release tablets
- Quantity: 30
- Product type: Original
- Price: 190.49 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.